Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease.
Level 4 - case-series / case-control
Cross-sectional comparative case-control tissue study in human post-mortem brain samples.
PubMed 25757756 · doi:10.1038/jcbfm.2015.44
What was done
The authors evaluated pericyte degeneration, blood-brain barrier (BBB) breakdown (leakage of immunoglobulin G and fibrin), accumulation of cyclophilin A (CypA) and matrix metalloproteinase-9 (MMP-9), and levels of low-density lipoprotein receptor-related protein-1 (LRP1) across three human groups: Alzheimer's disease (AD) APOE4 carriers, AD APOE3 carriers, and non-AD controls.
What was found
The abstract reports no numerical values, effect sizes, or statistical parameters. It reports directional findings: pericyte degeneration was greatest in AD APOE4 carriers, followed by AD APOE3 carriers, and lowest in non-AD controls (AD APOE4 > AD APOE3 > controls). This loss correlated with the magnitude of BBB breakdown to IgG and fibrin. CypA and MMP-9 accumulation in pericytes and endothelial cells was higher in APOE4 carriers than APOE3 carriers. LRP1 levels were reduced to a similar extent in both AD APOE4 and APOE3 groups.
Why it matters
This study provides human tissue evidence linking the APOE4 genetic risk factor to accelerated pericyte loss and CypA–MMP-9 pathway activation, clarifying a vascular mechanism for increased BBB breakdown in Alzheimer's disease.
Limits
The abstract provides no sample sizes (n is unstated), donor demographics, quantitative measurements, or p-values. The cross-sectional tissue design precludes establishing the temporal sequence of vascular degradation and neurodegeneration in living patients.
Cited by
- supports APOE4 has lower binding affinity for the LRP1 receptor on pericytes than APOE3, triggering an NF-κB and cyclophilin A signaling cascade that drives MMP-9 expression.
- supports Cultured human iPSC-derived pericytes from APOE4 donors produce more cyclophilin A and MMP-9 at baseline than pericytes from APOE3 donors.